VivoSeq
Infectious Disease

Toxoplasmosis

7

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Toxoplasmosis is an early-stage landscape with 7 programs across 2 companies. The most active players are Eastern Cooperative Oncology Group, Astellas. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Terminated1 · 33%

Clinical Trials

Trial Activity

Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis
Completed·UUniversity of Campinas, Brazil·Phase 3·NCT01449877·141 enrolled
Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis
Terminated·UUniversity Hospital, Strasbourg, France·N/A·NCT02863588·16 enrolled
Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis
Completed·UUniversity Hospital, Grenoble·N/A·NCT02843438·72 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)